Claus Spies, MD
Nephrology · Melbourne, FLNPI 1619952769
Payments from drug & device makers
Across 147 payments — averaging $5811.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$774K
- Vertex$77K
- Bayer$639
- Fresenius USA Marketing, Inc.$250
- Amgen$212
- Nxstage Medical, Inc.$206
- plus $1K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 54 | $774,438 |
| Vertex | 1 | $77,254 |
| Bayer | 19 | $639 |
| Fresenius USA Marketing, Inc. | 13 | $250 |
| Amgen(2 entities) | 6 | $212 |
| Nxstage Medical, Inc. | 2 | $206 |
| OPKO Pharmaceuticals, LLC | 10 | $195 |
| Otsuka America Pharmaceutical, Inc. | 8 | $163 |
| Travere Therapeutics, Inc. | 2 | $144 |
| Vantive US Healthcare LLC | 2 | $130 |
| Akebia Therapeutics Inc | 6 | $127 |
| Baxter Healthcare | 1 | $104 |
| Vifor Pharma, Inc. | 6 | $100 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Novartis | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $32 |
| Ardelyx, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $23 |
| GSK | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
How this compares
$854,323 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Melbourne
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.